Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.

Edlund H, Lee SK, Andrew MA, Slatter JG, Aksenov S, Al-Huniti N.

Clin Pharmacokinet. 2018 Dec 17. doi: 10.1007/s40262-018-0725-7. [Epub ahead of print]

PMID:
30556110
2.

Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.

Podoll T, Pearson PG, Evarts J, Ingallinera T, Bibikova E, Sun H, Gohdes M, Cardinal K, Sanghvi M, Slatter JG.

Drug Metab Dispos. 2019 Feb;47(2):145-154. doi: 10.1124/dmd.118.084459. Epub 2018 Nov 15.

PMID:
30442651
3.

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W.

Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.

PMID:
29241979
4.

Evaluation of Evolocumab (AMG 145), a Fully Human Anti-PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment.

Gibbs JP, Slatter JG, Egbuna O, Geller M, Hamilton L, Dias CS, Xu RY, Johnson J, Wasserman SM, Emery MG.

J Clin Pharmacol. 2017 Apr;57(4):513-523. doi: 10.1002/jcph.832. Epub 2016 Oct 26.

5.

Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis.

Subramanian R, Zhu X, Hock MB, Sloey BJ, Wu B, Wilson SF, Egbuna O, Slatter JG, Xiao J, Skiles GL.

Clin Pharmacokinet. 2017 Feb;56(2):179-192. doi: 10.1007/s40262-016-0433-0.

6.

An open-label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners.

Sohn W, Lee E, Kankam MK, Egbuna O, Moffat G, Bussiere J, Padhi D, Ng E, Kumar S, Slatter JG.

Br J Clin Pharmacol. 2016 Feb;81(2):362-9. doi: 10.1111/bcp.12798. Epub 2015 Dec 5.

7.

Therapeutic protein drug-drug interactions: navigating the knowledge gaps-highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA workshop.

Kenny JR, Liu MM, Chow AT, Earp JC, Evers R, Slatter JG, Wang DD, Zhang L, Zhou H.

AAPS J. 2013 Oct;15(4):933-40. doi: 10.1208/s12248-013-9495-1. Epub 2013 Jun 21.

8.

Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper.

Evers R, Dallas S, Dickmann LJ, Fahmi OA, Kenny JR, Kraynov E, Nguyen T, Patel AH, Slatter JG, Zhang L.

Drug Metab Dispos. 2013 Sep;41(9):1598-609. doi: 10.1124/dmd.113.052225. Epub 2013 Jun 21. Review.

PMID:
23792813
9.

Activity-based exposure comparisons among humans and nonclinical safety testing species in an extensively metabolized drug candidate.

Zhu X, Slatter JG, Emery MG, Deane MR, Akrami A, Zhang X, Hickman D, Skiles GL, Subramanian R.

Xenobiotica. 2013 Jul;43(7):617-27. doi: 10.3109/00498254.2012.747711. Epub 2012 Dec 17.

PMID:
23244593
10.

Effects of interleukin 1β (IL-1β) and IL-1β/interleukin 6 (IL-6) combinations on drug metabolizing enzymes in human hepatocyte culture.

Dickmann LJ, Patel SK, Wienkers LC, Slatter JG.

Curr Drug Metab. 2012 Sep 1;13(7):930-7.

PMID:
22475267
11.

Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression.

Dickmann LJ, McBride HJ, Patel SK, Miner K, Wienkers LC, Slatter JG.

Biochem Pharmacol. 2012 Jun 15;83(12):1682-9. doi: 10.1016/j.bcp.2012.03.001. Epub 2012 Mar 10.

PMID:
22425536
12.

Regiospecific and stereospecific triangulation of the structures of metabolites formed by sequential metabolism at multiple prochiral centers.

Greene RJ, Davis JA, Subramanian R, Deane MR, Emery MG, Slatter JG.

Drug Metab Dispos. 2012 May;40(5):928-42. doi: 10.1124/dmd.111.043166. Epub 2012 Feb 10.

PMID:
22328582
13.

Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture.

Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG.

Drug Metab Dispos. 2011 Aug;39(8):1415-22. doi: 10.1124/dmd.111.038679. Epub 2011 May 9.

PMID:
21555507
14.

Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY.

Genome Res. 2010 Aug;20(8):1020-36. doi: 10.1101/gr.103341.109. Epub 2010 Jun 10.

15.
16.

Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.

Foti RS, Dickmann LJ, Davis JA, Greene RJ, Hill JJ, Howard ML, Pearson JT, Rock DA, Tay JC, Wahlstrom JL, Slatter JG.

Xenobiotica. 2008 Mar;38(3):264-80. doi: 10.1080/00498250701802514 .

PMID:
18274956
17.

In vitro metabolic activation of lumiracoxib in rat and human liver preparations.

Li Y, Slatter JG, Zhang Z, Li Y, Doss GA, Braun MP, Stearns RA, Dean DC, Baillie TA, Tang W.

Drug Metab Dispos. 2008 Feb;36(2):469-73. Epub 2007 Nov 12.

PMID:
17998295
18.

Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia.

Lum PY, He YD, Slatter JG, Waring JF, Zelinsky N, Cavet G, Dai X, Fong O, Gum R, Jin L, Adamson GE, Roberts CJ, Olsen DB, Hazuda DJ, Ulrich RG.

Genomics. 2007 Oct;90(4):464-73. Epub 2007 Aug 23.

19.

Advances in predicting CYP-mediated drug interactions in the drug discovery setting.

Wahlstrom JL, Rock DA, Slatter JG, Wienkers LC.

Expert Opin Drug Discov. 2006 Dec;1(7):677-91. doi: 10.1517/17460441.1.7.677.

PMID:
23495993
20.

Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.

Bleasby K, Castle JC, Roberts CJ, Cheng C, Bailey WJ, Sina JF, Kulkarni AV, Hafey MJ, Evers R, Johnson JM, Ulrich RG, Slatter JG.

Xenobiotica. 2006 Oct-Nov;36(10-11):963-88.

PMID:
17118916
21.

Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome.

Slatter JG, Templeton IE, Castle JC, Kulkarni A, Rushmore TH, Richards K, He Y, Dai X, Cheng OJ, Caguyong M, Ulrich RG.

Xenobiotica. 2006 Oct-Nov;36(10-11):938-62.

PMID:
17118915
22.

Microarray-based compendium of hepatic gene expression profiles for prototypical ADME gene-inducing compounds in rats and mice in vivo.

Slatter JG, Cheng O, Cornwell PD, de Souza A, Rockett J, Rushmore T, Hartley D, Evers R, He Y, Dai X, Hu R, Caguyong M, Roberts CJ, Castle J, Ulrich RG.

Xenobiotica. 2006 Oct-Nov;36(10-11):902-37.

PMID:
17118914
23.

Profiling the hepatic effects of flutamide in rats: a microarray comparison with classical aryl hydrocarbon receptor ligands and atypical CYP1A inducers.

Coe KJ, Nelson SD, Ulrich RG, He Y, Dai X, Cheng O, Caguyong M, Roberts CJ, Slatter JG.

Drug Metab Dispos. 2006 Jul;34(7):1266-75. Epub 2006 Apr 12.

PMID:
16611858
24.

The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E.

Gordi T, Tan LH, Hong C, Hopkins NJ, Francom SF, Slatter JG, Antal EJ.

J Clin Pharmacol. 2003 Oct;43(10):1161-7.

PMID:
14517199
25.

Assessment of radioactive residues arising from radiolabel instability in a multiple dose tissue distribution study in rats.

Slatter JG, Sams JP, Easter JA, Fate GD, Chiba K, Johnson MG, Courtney M, Koets MD, Norris LR, Jones BW.

Biol Pharm Bull. 2003 May;26(5):573-8.

26.

Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.

Barbachyn MR, Cleek GJ, Dolak LA, Garmon SA, Morris J, Seest EP, Thomas RC, Toops DS, Watt W, Wishka DG, Ford CW, Zurenko GE, Hamel JC, Schaadt RD, Stapert D, Yagi BH, Adams WJ, Friis JM, Slatter JG, Sams JP, Oien NL, Zaya MJ, Wienkers LC, Wynalda MA.

J Med Chem. 2003 Jan 16;46(2):284-302.

PMID:
12519066
27.

Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog.

Slatter JG, Adams LA, Bush EC, Chiba K, Daley-Yates PT, Feenstra KL, Koike S, Ozawa N, Peng GW, Sams JP, Schuette MR, Yamazaki S.

Xenobiotica. 2002 Oct;32(10):907-24.

PMID:
12419019
28.

Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.

Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, Shobe EM.

Drug Metab Dispos. 2001 Aug;29(8):1136-45.

PMID:
11454733
29.

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.

Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd.

Drug Metab Dispos. 2000 Apr;28(4):423-33.

PMID:
10725311
30.

Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion.

Wang Y, Mesfin GM, Rodríguez CA, Slatter JG, Schuette MR, Cory AL, Higgins MJ.

Pharm Res. 1999 Jun;16(6):930-8.

PMID:
10397616
31.

Absorption, distribution, metabolism, and excretion of atevirdine in the rat.

Chang M, Sood VK, Wilson GJ, Kloosterman DA, Sanders PE, Schuette MR, Judy RW, Voorman RL, Maio SM, Slatter JG.

Drug Metab Dispos. 1998 Oct;26(10):1008-18.

PMID:
9763407
32.

Metabolism of a bisphosphonate ester (PNU-91638) in rat.

Slatter JG, Feenstra KL, Hauer MJ, Sanders PE, Vrbanac JJ, Scott G, Speed W.

Xenobiotica. 1997 Oct;27(10):1039-51.

PMID:
9364741
33.
34.

Pharmacokinetics and metabolism of the novel anticonvulsant agent N-(2,6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide (D2624) in rats and humans.

Martin SW, Bishop FE, Kerr BM, Moor M, Moore M, Sheffels P, Rashed M, Slatter JG, Berthon-Cédille L, Lepage F, Descombe JJ, Picard M, Baillie TA, Levy RH.

Drug Metab Dispos. 1997 Jan;25(1):40-6.

PMID:
9010628
35.

Biotransformation of lifibrol (U-83860) to mixed glyceride metabolites by rat and human hepatocytes in primary culture.

Sun EL, Feenstra KL, Bell FP, Sanders PE, Slatter JG, Ulrich RG.

Drug Metab Dispos. 1996 Feb;24(2):221-31.

PMID:
8742235
36.

Metabolism of the bisphosphonate ester U-91502 in rats.

Slatter JG, Feenstra KL, Hauer MJ, Kloosterman DA, Parton AH, Sanders PE, Scott G, Speed W.

Drug Metab Dispos. 1996 Jan;24(1):65-73.

PMID:
8825192
37.

Studies on the metabolic fate of caracemide, an experimental antitumor agent, in the rat. Evidence for the release of methyl isocyanate in vivo.

Slatter JG, Davis MR, Han DH, Pearson PG, Baillie TA.

Chem Res Toxicol. 1993 May-Jun;6(3):335-40.

PMID:
8318655
38.
39.

In vitro and in vivo investigations of dihydropyridine-based chemical delivery systems for anticonvulsants.

Boddy AV, Zhang K, Lepage F, Tombret F, Slatter JG, Baillie TA, Levy RH.

Pharm Res. 1991 Jun;8(6):690-7.

PMID:
2062798
40.
41.
42.

Identification of the biliary metabolites of (+/-)-3-dimethylamino-1,1-diphenylbutane HCl (recipavrin) in rats.

Slatter JG, Abbott FS, Burton R.

Xenobiotica. 1990 Oct;20(10):999-1024.

PMID:
2082598
43.

S-(N-methylcarbamoyl)glutathione: a reactive S-linked metabolite of methyl isocyanate.

Pearson PG, Slatter JG, Rashed MS, Han DH, Grillo MP, Baillie TA.

Biochem Biophys Res Commun. 1990 Jan 15;166(1):245-50.

PMID:
2302207
44.

Biotransformation of aliphatic formamides: metabolites of (+-)-N-methyl-N-(1-methyl-3,3-diphenylpropyl) formamide in rats.

Slatter JG, Mutlib AE, Abbott FS.

Biomed Environ Mass Spectrom. 1989 Sep;18(9):690-701.

PMID:
2790257
45.

Methadone metabolism in the rat in vivo: identification of a novel formamide metabolite.

Abbott FS, Slatter JG, Burton R, Kang GI.

Xenobiotica. 1985 Feb;15(2):129-40.

PMID:
4002735

Supplemental Content

Loading ...
Support Center